Craig  Fraser net worth and biography

Craig Fraser Biography and Net Worth

Craig was appointed Windtree’s President and Chief Executive Officer in February 2016 in addition to joining as a member of the Board of Directors.

Craig brings more than 29 years of experience as a leader in product development and commercial operations and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining Windtree, Craig held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Novelion (AEGR) Therapeutics, Vice President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Craig is a veteran of both the U.S. Marine Corps and the U.S. Army.

What is Craig Fraser's net worth?

The estimated net worth of Craig Fraser is at least $19,603.46 as of September 26th, 2023. Mr. Fraser owns 55,377 shares of Windtree Therapeutics stock worth more than $19,603 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Fraser may own. Additionally, Mr. Fraser receives an annual salary of $553,750.00 as CEO at Windtree Therapeutics. Learn More about Craig Fraser's net worth.

How old is Craig Fraser?

Mr. Fraser is currently 59 years old. There are 4 older executives and no younger executives at Windtree Therapeutics. Learn More on Craig Fraser's age.

What is Craig Fraser's salary?

As the CEO of Windtree Therapeutics, Inc., Mr. Fraser earns $553,750.00 per year. Learn More on Craig Fraser's salary.

How do I contact Craig Fraser?

The corporate mailing address for Mr. Fraser and other Windtree Therapeutics executives is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. Windtree Therapeutics can also be reached via phone at (215) 488-9300 and via email at [email protected]. Learn More on Craig Fraser's contact information.

Has Craig Fraser been buying or selling shares of Windtree Therapeutics?

Craig Fraser has not been actively trading shares of Windtree Therapeutics during the last quarter. Most recently, on Tuesday, September 26th, Craig Fraser bought 2,500 shares of Windtree Therapeutics stock. The stock was acquired at an average cost of $0.90 per share, with a total value of $2,250.00. Following the completion of the transaction, the chief executive officer now directly owns 55,377 shares of the company's stock, valued at $49,839.30. Learn More on Craig Fraser's trading history.

Who are Windtree Therapeutics' active insiders?

Windtree Therapeutics' insider roster includes Craig Fraser (CEO), and James Huang (Director). Learn More on Windtree Therapeutics' active insiders.

Are insiders buying or selling shares of Windtree Therapeutics?

In the last year, Windtree Therapeutics insiders bought shares 2 times. They purchased a total of 3,815 shares worth more than $4,735.35. The most recent insider tranaction occured on September, 26th when CEO Craig Fraser bought 2,500 shares worth more than $2,250.00. Insiders at Windtree Therapeutics own 0.5% of the company. Learn More about insider trades at Windtree Therapeutics.

Information on this page was last updated on 9/26/2023.

Craig Fraser Insider Trading History at Windtree Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/26/2023Buy2,500$0.90$2,250.0055,377View SEC Filing Icon  
4/25/2023Buy1,315$1.89$2,485.355,513View SEC Filing Icon  
7/26/2022Buy25$37.00$925.002,240View SEC Filing Icon  
6/29/2022Buy70$42.00$2,940.002,170View SEC Filing Icon  
3/15/2022Buy30$98.00$2,940.00View SEC Filing Icon  
11/18/2021Buy9$161.00$1,449.00View SEC Filing Icon  
10/22/2021Buy30$190.00$5,700.00View SEC Filing Icon  
10/19/2021Buy30$191.00$5,730.00View SEC Filing Icon  
4/5/2021Buy10$258.00$2,580.00277View SEC Filing Icon  
3/31/2021Buy5$232.00$1,160.00262View SEC Filing Icon  
10/28/2020Buy2$656.00$1,312.00242View SEC Filing Icon  
10/9/2020Buy2$583.00$1,166.00240View SEC Filing Icon  
10/7/2020Buy2$517.00$1,034.00237View SEC Filing Icon  
10/28/2016Buy75$205.00$15,375.0075View SEC Filing Icon  
See Full Table

Craig Fraser Buying and Selling Activity at Windtree Therapeutics

This chart shows Craig Fraser's buying and selling at Windtree Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Windtree Therapeutics Company Overview

Windtree Therapeutics logo
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Read More

Today's Range

Now: $0.35
Low: $0.35
High: $0.37

50 Day Range

MA: $0.38
Low: $0.31
High: $0.51

2 Week Range

Now: $0.35
Low: $0.28
High: $18.48

Volume

28,816 shs

Average Volume

63,097 shs

Market Capitalization

$1.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6